The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...

Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...